Results 211 to 220 of about 3,235 (226)

Omalizumab/tezepelumab

Reactions Weekly
openaire   +1 more source

Tezepelumab for severe asthma – an “all round” player

European Journal of Internal Medicine
Ophir Freund, Hitasha Rupani, Brian Lipworth, Rory Chan   +3 more
openaire   +2 more sources

Tezepelumab Reduces and Eliminates OCS Use in OCS-Dependent Patients With Severe Asthma: Primary Results From the Phase 3b WAYFINDER Study

American Journal of Respiratory and Critical Care Medicine
D. Jackson, N. Lugogo, M. Gurnell, L. Heaney, S. Korn, G. Brusselle, P. Chanez, R. Del Olmo, J.-P. Llanos, N. Keeling, K. Sałapa, B. Cook, K. Kostikas, R. Fogel, N. Martin, S. Chandarana   +15 more
semanticscholar   +1 more source

Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma

Immunotherapy, 2023
exaly  

Cotrimoxazole/dupilumab/tezepelumab

Reactions Weekly
openaire   +1 more source

Tezepelumab Home Use Study

Case Medical Research, 2019
openaire   +1 more source

Dupilumab/Omalizumab/Tezepelumab

Reactions Weekly
openaire   +1 more source

Tezepelumab (Tezspire) for severe asthma.

The Medical letter on drugs and therapeutics, 2022
openaire   +1 more source

Tezepelumab in eosinophilic granulomatosis with polyangiitis (EGPA)

Airway pharmacology and treatment
Alexandra Nanzer, Anne-Catherine Maynard-Paquette, Jessica Gates, Faizan Harris, Cris Roxas, Linda Green, Mariana Fernandes, Louise Thomson, Jodie Lam, Grainne D'Ancona, Claire Hopkins, Michelle Fernando, Tevfik Ismail, Jaideep Dhariwal, David Jackson   +14 more
openaire   +1 more source

Tezepelumab in patients with allergic and eosinophilic asthma

Allergy: European Journal of Allergy and Clinical Immunology
Ian Pavord, Marek Lommatzsch, Andrea Matucci   +2 more
exaly